松下(PCRFY.US)將於3月底開始批量生產4680特斯拉電池
格隆匯2月28日丨據路透,松下(PCRFY.US)週一表示,將在3月底之前在日本的一家工廠開始批量生產特斯拉公司(TSLA.US)的新型鋰離子電池。公司於10月公佈了4680格式(寬46毫米,高80毫米)的電池,比目前供應給特斯拉的電池大5倍,這意味着特斯拉能夠降低生產成本,也有望提高汽車的續航里程,這可能有助於特斯拉吸引更多的司機使用電動汽車。松下在一份新聞稿中表示,該公司將在其位於日本西部和Wakayama的工廠建造兩條新生產線來生產這種電池。據日經新聞早間消息稱,松下計劃向該工廠投資800億日圓(約合6.92億美元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.